Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy.

Richardson CM; Sharma RA; Cox GOByrne KJ

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy.

【24h】

Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy.

机译：表皮生长因子受体和cyclooxygenase-2发病机理的非小细胞肺癌:潜在的目标化学预防和系统性治疗。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The epidermal growth factor receptor (EGFR) is part of a family of plasma membrane receptor tyrosine kinases that control many important cellular functions, from growth and proliferation to cell death. Cyclooxygenase (COX)-2 is an enzyme which catalyses the conversion of arachidonic acid to prostagladins and thromboxane. It is induced by various inflammatory stimuli, including the pro-inflammatory cytokines, Interleukin (IL)-1beta, Tumour Necrosis Factor (TNF)-alpha and IL-2. Both EGFR and COX-2 are over-expressed in non-small cell lung cancer (NSCLC) and have been implicated in the early stages of tumourigenesis. This paper considers their roles in the development and progression of lung cancer, their potential interactions, and reviews the recent progress in cancer therapies that are directed toward these targets. An increasing body of evidence suggests that selective inhibitors of both EGFR and COX-2 are potential therapeutic agents for the treatment of NSCLC, in the adjuvant, metastatic and chemopreventative settings.

机译：表皮生长因子受体(EGFR)质膜受体家族的一部分酪氨酸激酶,许多重要的控制从生长和增殖细胞功能细胞死亡。酶的催化作用的转换prostagladins和花生四烯酸凝血恶烷。炎症刺激,包括促炎细胞因子、白介素(IL) 1β,肿瘤坏死因子(TNF) - alpha和2。在非小细胞肺癌(NSCLC)和涉及的早期阶段tumourigenesis。在肺的开发和发展癌症、潜在的相互作用和评论癌症治疗的最新进展针对这些目标。的证据表明选择性抑制剂表皮生长因子受体和cox - 2都是潜在的治疗药物治疗非小细胞肺癌,佐剂,转移和chemopreventative设置。

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer》 |2003年第1期|1-13|共13页
作者
Richardson CM; Sharma RA; Cox GOByrne KJ;
展开▼
作者单位

Department of Oncology, University of Leicester, Osborne Building, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, LEI 5WW, Leicester, UK;

P.O. Box 7558, Newark, De 19714, Delaware;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类肿瘤学;
关键词
systemic therapy; Non-Small-Cell Lung Carcinoma; ErbB ReceptorsGrowth Factor ReceptorsthromboxaneCyclooxygenase 2Lung CancerChemopreventioncancer therapyProstaglandin-Endoperoxide SynthasesReceptor;

机译：系统性疗法;非小细胞肺癌癌;ErbB ReceptorsGrowth因素ReceptorsthromboxaneCyclooxygenase 2肺CancerChemopreventioncancertherapyProstaglandin-EndoperoxideSynthasesReceptor;

相似文献

外文文献
中文文献

1. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations [J] . Yan Zhang, Zheng Wang, Xuezhi Hao, 中国癌症研究（英文版） . 2017,第001期
2. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation [O] . Jiang, ZH, Zhou, YL, Yau, LF, 2016

机译：Targeting Tyrosine Kinase Inhibitor-Resistant Non-small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via methionine 790 Oxidation

Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy.

摘要

著录项

相似文献

相关主题

期刊订阅